Background: Breast cancer subtype is a key determinant in treatment decision-making, and also effects survival outcome. In this population-based study, in-depth analyses were performed to examine the impact that breast cancer subtype and receipt of guideline-concordant adjuvant systemic therapy (AST) have on survival using a population-based cancer registry’s data. Methods: Women aged ≥20 years with microscopically confirmed stage I–III breast cancer diagnosed in 2011 were identified from the Louisiana Tumor Registry. Breast cancer subtypes were categorized based on hormone receptor (HR) and HER2 status. Guideline-concordant treatment was defined using the NCCN Guidelines for Breast Cancer. Logistic regression was applied to identify factors associated with guideline-concordant AST receipt. Kaplan-Meier survival curves were generated to compare survival among subtypes by AST receipt status, and a semiparametric additive hazard model was used to verify the factors impacting survival outcome. Results: Of 2,214 eligible patients, most (70.8%) were HR+/HER2– followed by HR–/HER2– (14.4%), and 78.6% received guideline-concordant AST. Compared with patients with the HR+/HER2+ subtype, women with other subtypes were more likely to be guideline-concordant after adjusting for sociodemographic and clinical variables. Women with the HR–/HER2+ or HR–/HER2– subtype had a higher risk of any-cause and breast cancer–specific death than those with the HR+/HER2+ subtype. Those who did not receive AST had an additional adjusted hazard of 0.0191 (P=.0001) in overall survival and 0.0126 (P=.0011) in cause-specific survival compared with those who received AST. Conclusions: Most patients received guideline-concordant AST, except for those with the HR+/HER2+ subtype. Patients receiving guideline-adherent adjuvant therapy had better survival outcomes across all breast cancer subtypes.
Submitted September 4, 2018; accepted for publication January 9, 2019.Author contributions:Study concept: Hsieh, Chen. Study design: Hsieh, Wu. Data collection and quality assessment: Davidson. Data analysis: Hsieh, Zhang. Guidance on clinical practice of breast cancer treatment: Loch. Writing—original draft and revision: Hsieh. Writing—review and editing: Zhang, Wu, Davidson, Loch, Chen.Disclosures: The authors have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.Funding: This work was supported in part by the CDC Cooperative Agreements of the National Program of Cancer Registries (grant/award number: U58DP003915) in conjunction with a CDC Comparative Effectiveness Research contract to ICF (grant/award number: 635243-10S-1566) and NCI’s contract number HHSN2612018000071.Disclaimer: The findings and conclusions are those of the authors and do not necessarily represent the official position of their affiliations, the CDC, or NCI.Correspondence: Mei-Chin Hsieh, PhD, Epidemiology Program and Louisiana Tumor Registry, School of Public Health, Louisiana State University Health Sciences Center, 2020 Gravier Street, New Orleans, LA 70112. Email: firstname.lastname@example.org
SotiriouC, NeoSY, McShaneLM, . Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393–10398.10.1073/pnas.1732912100)| false
Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717.
Early Breast Cancer Trialists’ Collaborative Group.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717.15894097)| false
BerryDA, CirrincioneC, HendersonIC, . Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658–1667.10.1001/jama.295.14.165816609087)| false
HarrisL, FritscheH, MennelR, . American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287–5312.10.1200/JCO.2007.14.2364)| false
Wu XC, Lund MJ, Kimmick GG, . Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 2012;30:142–150.
WuXC, LundMJ, KimmickGG, . Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 2012;30:142–150.10.1200/JCO.2011.36.839922147735)| false
ZurawskaU, BaribeauDA, GiilckS, . Outcomes of HER2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients. Curr Oncol 2013;20:e539–545.10.3747/co.20.1523)| false
PaikS.Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 2007;12:631–635.10.1634/theoncologist.12-6-63117602054)| false
American College of Surgeons, Commission on Cancer. Facility Oncology Registry Data Standards. Revised for 2011. Available at: https://www.facs.org/∼/media/files/quality%20programs/cancer/coc/fords/fords_for_2011_01012011.ashx. Accessed May 25, 2017.)| false
Xie X, Strickler HD, Xue X. Additive hazard regression models: an application to the natural history of human papillomavirus. Comput Math Methods Med 2013;796270. http://dx.doi.org/10.1155/2013/796270.
Verschoor AM, Kuijer A, Verloop J, . Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level. Breast Cancer Res Treat 2016;159:357–365.
VerschoorAM, KuijerA, VerloopJ, . Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level. Breast Cancer Res Treat 2016;159:357–365.10.1007/s10549-016-3940-7)| false
O’BrienKM, ColeSR, TseCK, . Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010;16:6100–6110.10.1158/1078-0432.CCR-10-153321169259)| false
Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol 2014;2014:469251.
PariseCA, CaggianoV.Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol 2014;2014:469251.10.1155/2014/469251)| false
HaqueR, AhmedSA, InzhakovaG, . Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev 2012;21:1848–1855.2298946110.1158/1055-9965.EPI-12-0474)| false